Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Pushes FDA For Narrower Policy On NDI Notifications

This article was originally published in The Tan Sheet

Executive Summary

FDA's expectation for firms to file new dietary ingredient notifications for all supplements that contain new ingredients "is tantamount to a registration process," industry leaders argue.

You may also be interested in...



Food Safety And Rising Costs Top 2012 Challenges For Supplement Industry

Rising costs could lead to quality control problems in 2012 if consumers will not pay higher prices to cover manufacturers’ higher costs. Continued implementation of food safety reform “is a big deal,” partly because the requirements may be causing higher costs, says Loren Israelsen of the UNPA.

Food Safety And Rising Costs Top 2012 Challenges For Supplement Industry

Rising costs could lead to quality control problems in 2012 if consumers will not pay higher prices to cover manufacturers’ higher costs. Continued implementation of food safety reform “is a big deal,” partly because the requirements may be causing higher costs, says Loren Israelsen of the UNPA.

Trade Groups Should Encourage Supplement NDI Compliance – Fabricant

NDI compliance is “taking a back seat to how people feel about the guidance,” FDA official Daniel Fabricant says. Industry leaders ask what more they can do to encourage NDI notification compliance, but also reiterate concerns about FDA’s draft guidance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel